Amgen is a well-versed player in the industry. Not only is it the leading global biotechnology company, but the company seems to know how to change its form to suit its environment, just like how Amgen Korea adjusts to Korea.

Since entering Korea in 2015, Amgen has added 6 of its launched products to the reimbursement list, including its osteoporosis drugs Prolia (denosumab) and Evenity (romosozumab), skeletal-related event prevention drug Xgeva (denosumab), dyslipidemia drug Repatha (evolocumab), acute leukemia drug Blincyto (blinatumomab), and multiple myeloma drug Kyprolis (carfilzomib). In addition, the company is actively working to expand coverage by adding indications for each drug.